Steering Comittee

 

Steering Committee

Involving all platform’s scientific players involved in carrying out projects and Protisvalor (administrative manager), the Steering Committee determines scientific strategy, ensures that it is applied by the platform’s executive committee and arbitrates requests, if necessary. Professor Eric Vivier is its scientific coordinator.
The Steering Committee meets every two months and prepares a progress report on both structuring and R&D projects.


Pr Eric VIVIER

Coordinateur (Aix-Marseille Université, CIML)

Professor of Immunology at the Faculté de Médecine de Marseille (Aix-Marseille University), Hospital Practitioner at the Assistance Publique des Hôpitaux de Marseille (and co-founder of Innate Pharma, Eric Vivier is the Director of the CIML (Centre d’Immunologie de Marseille-Luminy) where his team studies Natural Killer cell biology.

A member of the Académie de Médecine, the Institut de France and the European Research Council Starting Grant’s Committee of Experts, Eric Vivier is the author of 11 patents and over 250 scientific publications.

With Eric Vivier, MI-mAbs gains the benefit of threefold scientific, clinical and industrial expertise because, as he was not satisfied with just contributing to the discovery of the mechanisms involved in activating NK lymphocytes, he also plays an active role in developing new immunotherapy strategies as well as their preclinical and clinical assessment.


Pr Jean Paul BORG

Institut Paoli-Calmettes, CRCM

Professor of cellular biology, Hospital Practitioner at Institut Paoli-Calmettes and Assistant Dean of the de la Faculté de Pharmacie de Marseille (Marseille School of Pharmacy), Jean Paul Borg is the Scientific Director of Institut Paoli-Calmettes (IPC) and Director of the CRCM (Centre de Cancérologie de Marseille) where his team studies the mechanisms that regulate the formation and dissemination of metastases.

Jean Paul Borg brings together researchers, engineers, specialists in translational medicine and clinicians to work hand-in-hand in a continuum that the strong point at the CRCM and beyond, at the Marseille Immunopole cluster.

Jean Paul Borg is a member of the Institut Universitaire de France, the bureau of experts at ITMO Cancer and the Scientific Councils of the PACA Canceropole and the Centre Léon Bérard in Lyon.


Dr Bernard MALISSEN

CIPHE

Bernard Malissen is one of the world’s pioneers in molecular immunology. Research Director at the CNRS, former Director of the CIML (Centre d’Immunologie de Marseille-Luminy), Founder and Director of CIPHE (Centre d’Immunophénomique), he has dedicated most of his work to studying antigen recognition and T-cell activation, as well as T-cell receptor genetics.

Recipient of the CNRS Silver Medal and winner of INSERM’s 2005 Grand Prix for Medical Research, Bernard Malissen is a member of the Académie des Sciences, EMBO and the Scientific Council at Innate Pharma, as well as an honorary member of the American Association of Immunologists.


Dr Hervé BRAILLY

Innate Pharma

Hervé Brailly is Chairman of the Board of Directors, Chief Executive Officer and co-founder of Innate Pharma. With François Romagné, he has transformed this young spin off from the CIML into a European leader in immuno-oncology, bringing 5 candidate drugs to clinics and signing front-line industrial partnerships.

Hervé Brailly is also a member of the bureau and treasurer of the Eurobiomed competitiveness cluster and member of the Board of Directors of INSERM Transfert and of the French biotechnology association, France Biotech.


Michel MANCIS

Protisvalor

Michel Mancis is the Manager of Protisvalor, Aix Marseille University’s research commercialization subsidiary. An experienced businessman, he has extensive managerial experience that has given him an in-depth understanding of healthcare businesses, from creation to management. At Protisvalor, he oversees the management of over 1,000 research contracts and 450 clinical trials, as well as 12 technological platforms with a team of 200 collaborators.

An active member of the subsidiary commission of the national C.U.R.I.E. network, Michel Mancis is also President of Progelife, a young SAS that works in the biotechnology field (Innovative Research Solutions for Healthy Aging).


Dr Magali AGNEL

Sanofi

Magali Agnel, PhD, is manager in the External Science and Innovation Team of Sanofi Global BioTherapeutics Dpt since May 2013. Leader of the project for Sanofi entry into MI-mAbs consortium, she is Sanofi scientific coordinator for MI-mAbs.

Magali Agnel has 20 years of experience as Research Group Leader in Sanofi. As such she contributed to many internal research programs with a specific focus on target identification and validation, as well as in vitro evaluation of biologics. Senior manager of the Biotherapeutics Dpt since 2006, Magali Agnel has a deep understanding of the whole value chain from the target to the clinics for biologics.

Magali Agnel has a PhD in Cellular Biology and Microbiology from Aix-Marseille II University (1981), a CES in Immunology from Aix-Marseille II Univ. (1984) and a DIU in Biotherapies and Immunology from Paris VI Univ. (2012).